KILITCH DRUGS INDIA LTD
KILITCH · FMCG · NSE
₹153
Current Market Price
Fair Value (DCF)
₹422
Margin of Safety
+176.1%
Updated 9h ago
YieldIQ Score
62/100
Piotroski F-Score
3/9
Economic Moat
Moderate
Confidence
25%
ROE
—
Debt/Equity
0.32
WACC
9.2%
Market Cap
₹534 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.3%
Return on capital employed
EV / EBITDA
19.2×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
7.8×
EBIT covers interest
Current Ratio
2.06×
Short-term liquidity
Asset Turnover
0.63×
Revenue per ₹ of assets
Revenue CAGR (3Y)
20.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹152.87
Bear case
₹267.1
MoS +42.8%
Base case
₹422
MoS +63.8%
Bull case
₹528.05
MoS +71.1%
Ratio Trends
KILITCH · last 8 annual periods
ROE
13.3%
ROCE
17.1%
Operating Margin
—
Debt / Equity
0.25×
PE
94.9×
EV / EBITDA
24.0×
Historical Financials
KILITCH · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹68.5 Cr | ₹114 Cr | ₹139 Cr | ₹154 Cr | ₹197 Cr | +30.3% |
| EBITDA | — | ₹13.3 Cr | ₹20.5 Cr | ₹28.6 Cr | ₹42.6 Cr | +33.9% |
| EBIT | ₹5.9 Cr | ₹10.8 Cr | ₹7.7 Cr | ₹6.6 Cr | — | +3.0% |
| PAT | ₹3.8 Cr | ₹6.2 Cr | ₹10.4 Cr | ₹14.6 Cr | ₹26.7 Cr | +63.2% |
| EPS (diluted) | ₹2.37 | ₹4.73 | ₹3.29 | ₹2.24 | — | -1.4% |
| CFO | ₹45.9 Cr | ₹5.8 Cr | ₹6.1 Cr | ₹-0.1 Cr | ₹17.5 Cr | -21.4% |
| CapEx | — | — | — | — | ₹-46.9 Cr | — |
| FCF | — | — | — | — | ₹-29.3 Cr | — |
| Total Assets | — | ₹210 Cr | ₹252 Cr | ₹240 Cr | ₹313 Cr | +10.5% |
| Total Debt | — | — | ₹21.9 Cr | ₹31.6 Cr | ₹49.4 Cr | +22.6% |
| Shareholders' Equity | — | — | ₹196 Cr | ₹176 Cr | ₹200 Cr | +0.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
KILITCH vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| AMANTA AMANTA HEALTHCARE LIMITED | -52.8% | 31 | Overvalued | 10.9% | — |
| ZIMLAB ZIM LABORATORIES LIMITED | -71.8% | 38 | Overvalued | 4.8% | — |
| ALBERTDAVD ALBERTDAVD | — | — | Pending | 4.4% | — |
| VALIANTLAB VALIANTLAB | — | — | Pending | -0.9% | — |
| MEDICAMEQ MEDICAMEQ | — | — | Pending | 3.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for KILITCH in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of KILITCH →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for KILITCH →
Compare
Head-to-head with peers
Compare KILITCH side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse KILITCHNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.